Actinic Keratosis Treatment

Actinic Keratosis Treatment Market Outlook

The global Actinic Keratosis Treatment Market is projected to reach approximately USD 4.5 billion by 2035, expanding at a CAGR of about 9.3% during the forecast period of 2025 to 2035. This significant growth can be attributed to a combination of factors including an increasing prevalence of actinic keratosis due to rising UV exposure, heightened public awareness regarding skin health, and advancements in treatment technologies. Additionally, the aging population is contributing to the market's expansion, as older adults are at a higher risk of developing actinic keratosis. The market is also seeing increased investments in dermatological research, which are fostering the development of more effective therapies. Furthermore, the rise in healthcare expenditure and favorable reimbursement policies are expected to provide additional momentum for market growth.

Growth Factor of the Market

One of the primary growth factors for the Actinic Keratosis Treatment Market is the increasing incidence of skin disorders attributed to prolonged exposure to ultraviolet (UV) radiation from the sun and artificial sources. As awareness regarding the dangers of UV rays increases, more individuals are seeking preventive measures and treatments for actinic keratosis. Furthermore, the expanding geriatric population is significantly contributing to the disease's prevalence, as older adults have thinner skin and a reduced ability to repair UV-induced damage. Advances in medical technology and the introduction of innovative treatment options are also key factors driving market growth. Additionally, the role of dermatologists and healthcare professionals in educating patients about the importance of early diagnosis and treatment cannot be overstated, as they encourage patients to seek timely interventions. Moreover, favorable government policies that support dermatological health and research play a vital role in enhancing treatment accessibility and affordability, further propelling market dynamics.

Key Highlights of the Market

• The market is projected to grow at a CAGR of 9.3% from 2025 to 2035.
• North America is anticipated to dominate the market share, accounting for over 40% of the global revenue.
• Topical medications are the most widely used treatment type, reflecting the growing preference for non-invasive therapies.
• Increasing public awareness regarding skin cancer risks is driving growth in preventive treatment options.
• Online pharmacies are gaining traction as a preferred distribution channel due to convenience and accessibility.

By Treatment Type

Topical Medications:

Topical medications represent a significant segment of the Actinic Keratosis Treatment Market, primarily due to their non-invasive nature and ease of application. These medications, which include 5-fluorouracil (5-FU), imiquimod, and diclofenac, are designed to be applied directly to the affected area, promoting the destruction of abnormal skin cells. The preference for topical treatments has increased due to their relatively low cost and the ability to be administered in an outpatient setting. Additionally, the growing emphasis on patient-centric care has led to the development of formulations that enhance patient adherence and improve outcomes. As a result, this segment is expected to witness substantial growth over the forecast period, fueled by ongoing research and the introduction of novel topical agents with improved efficacy and safety profiles.

Photodynamic Therapy:

Photodynamic therapy (PDT) is gaining momentum as an effective treatment option for actinic keratosis, characterized by the use of light-sensitive compounds activated by specific wavelengths of light to destroy abnormal skin cells. This therapeutic approach offers several advantages, including minimal invasiveness, quick recovery times, and the ability to target lesions precisely. The increasing prevalence of actinic keratosis, coupled with a growing preference for non-invasive treatment options, is expected to enhance the adoption of PDT in clinical settings. Additionally, advancements in light source technologies and photosensitizing agents continue to improve treatment outcomes, further driving the market. With ongoing clinical studies evaluating the long-term efficacy and safety of PDT, this segment is anticipated to experience significant growth throughout the forecast period.

Cryotherapy:

Cryotherapy, a well-established method for treating actinic keratosis, involves the application of extreme cold to freeze and destroy abnormal skin cells. This treatment is favored for its simplicity, speed, and effectiveness, making it a popular choice among healthcare providers and patients alike. The procedure can be performed in outpatient settings with minimal discomfort and leads to quick healing times. As awareness regarding skin cancer prevention increases, more patients are seeking cryotherapy as a viable treatment option. Furthermore, the rising number of dermatology clinics and healthcare facilities offering cryotherapy services is expected to contribute positively to the growth of this segment. The combination of rising demand for effective therapies and the continuous evolution of cryotherapy techniques positions this treatment type as a strong contender in the Actinic Keratosis Treatment Market.

Surgical Procedures:

Surgical procedures for the treatment of actinic keratosis, such as excision and curettage, are essential components of the market. These procedures are typically recommended for patients with extensive lesions or those that have progressed to more severe forms of skin damage. The effectiveness of surgical methods in providing immediate results and long-term resolution of lesions makes them attractive options for both patients and healthcare providers. Despite the higher cost and potential for scarring associated with surgical interventions, many patients prefer these methods when topical treatments are deemed insufficient. As advancements in surgical techniques and technologies continue to develop, it is anticipated that this segment will witness steady growth, especially among patients seeking definitive treatments.

Laser Therapy:

Laser therapy is increasingly being utilized as a modern treatment option for actinic keratosis, leveraging focused light energy to remove damaged skin layers while promoting skin rejuvenation. Various laser techniques such as ablative and non-ablative lasers offer different benefits tailored to specific patient needs, including minimal downtime and improved cosmetic outcomes. The growing demand for non-invasive and effective treatment options has propelled the adoption of laser therapies in dermatological practices. As research continues to improve laser technologies and expand their applications, this segment is expected to showcase robust growth. Furthermore, the rise in aesthetic treatments for skin rejuvenation is likely to fuel interest in laser therapy as a dual-purpose solution, addressing both therapeutic and cosmetic concerns.

By User

Hospitals:

Hospitals play a crucial role in the Actinic Keratosis Treatment Market, serving as primary healthcare facilities where patients receive comprehensive treatment for various skin disorders. Within hospital settings, patients benefit from multidisciplinary care approaches that encompass dermatology, oncology, and surgical specialties. Hospitals are equipped with advanced technologies and treatment options, making them ideal locations for complex cases requiring immediate intervention. Additionally, the presence of trained healthcare professionals in hospitals provides patients with a higher level of care and support. As the prevalence of actinic keratosis continues to rise, hospitals are expected to experience increased patient volumes seeking both preventive and therapeutic treatments, driving growth in this segment.

Dermatology Clinics:

Dermatology clinics specialize in skin-related ailments, including actinic keratosis, and are pivotal to the treatment landscape. These clinics offer personalized care and access to a wide range of treatment modalities tailored to individual patient needs. The increasing trend of patients directly consulting dermatologists for skin issues has bolstered the importance of dermatology clinics. With the ongoing advancements in dermatological research and treatment options, these clinics are often the first point of contact for patients seeking advice and intervention for actinic keratosis. As more patients recognize the importance of specialized care in managing skin disorders, dermatology clinics are expected to witness significant growth, further advancing the overall market for actinic keratosis treatments.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are emerging as a vital segment in the Actinic Keratosis Treatment Market, providing patients with same-day surgical services for various dermatological procedures. ASCs facilitate cost-effective, efficient care, enabling patients to undergo treatments such as cryotherapy and laser therapy without the need for hospital admission. The convenience of outpatient services has led to increased patient satisfaction and minimized disruption to daily life. Moreover, the growing preference for minimally invasive treatments that require shorter recovery times aligns with the services offered by ASCs. As more patients seek accessible and specialized care for actinic keratosis, the role of ambulatory surgical centers in the treatment landscape is expected to expand significantly.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies are essential distribution channels for actinic keratosis treatments, offering a wide range of medications and therapies directly to patients receiving care within hospital settings. These pharmacies are equipped to provide specialized medications, including topical agents and other dermatological products tailored for actinic keratosis. The advantage of having an on-site pharmacy allows for immediate access to necessary treatments, facilitating timely interventions post-diagnosis. Furthermore, hospital pharmacies often have access to the latest formulations and emerging therapies, enhancing the quality of care provided to patients. As the focus on integrated healthcare continues to rise, hospital pharmacies will play an increasingly significant role in the overall treatment continuum for actinic keratosis.

Retail Pharmacies:

Retail pharmacies serve as a crucial distribution channel for actinic keratosis treatments, providing patients with convenient access to topical medications and over-the-counter products. The widespread availability of retail pharmacies ensures that patients can easily obtain necessary treatments without the need for specialized medical appointments. Additionally, retail pharmacies often provide consultation services, empowering patients with valuable information regarding their treatment options. As patient awareness concerning actinic keratosis grows, the demand for accessible treatments from retail pharmacies is expected to increase. This segment is particularly important for preventive care, as patients can readily purchase topical agents to manage early-stage lesions before they develop into more serious conditions.

Online Pharmacies:

Online pharmacies are rapidly gaining popularity as a distribution channel for actinic keratosis treatments, facilitating the convenience of purchasing medications from the comfort of home. The rise of e-commerce in the pharmaceutical sector has made it easier for patients to access a diverse range of treatments, including prescription and over-the-counter options. Online pharmacies offer advantages such as discreet purchasing, home delivery, and often lower prices, making them appealing to patients who may feel self-conscious about seeking treatment in person. As the digitalization of healthcare accelerates, the role of online pharmacies in the actinic keratosis treatment landscape is anticipated to grow, providing patients with alternative options for acquiring necessary therapies.

By Product Type

Creams:

Creams are among the most commonly used formulations for the treatment of actinic keratosis, primarily due to their ease of use and effectiveness in delivering active ingredients to the affected area. These topical formulations often include agents such as 5-fluorouracil and imiquimod, which work by promoting the immune response against abnormal cells. The growing preference for topical treatments over invasive procedures has led to an increased demand for medicated creams in recent years. Furthermore, the emphasis on patient-centric care has spurred the development of user-friendly cream formulations that enhance patient compliance and treatment efficacy. As awareness of skin health continues to rise, the creams segment is expected to contribute significantly to market growth.

Gels:

Gels are another popular formulation in the Actinic Keratosis Treatment Market, offering a lightweight and easily absorbable option for patients. The gel form allows for smooth application and quick drying, making it a preferred choice for those seeking effective topical therapies. Similar to creams, gels may contain active ingredients that target abnormal skin cells. The development of gel formulations that minimize side effects and improve patient comfort has further enhanced their attractiveness in the market. As patients increasingly seek effective yet convenient treatment options, the gel segment is projected to experience robust growth, bolstered by ongoing innovations in dermatological formulations.

Solutions:

Solutions, often in liquid form, cater to specific treatment needs for actinic keratosis, providing alternative delivery methods for active ingredients. These formulations may contain a variety of compounds designed to address different stages of actinic keratosis. Solutions can be particularly beneficial for treating large areas of skin or hard-to-reach lesions. Their fluid consistency allows for even distribution and thorough coverage of affected areas. The growing interest in combination therapies, where solutions may be used alongside other topical agents, is likely to further stimulate demand for this segment. As patient preferences evolve, the solutions segment will continue to play a significant role in the overall actinic keratosis treatment landscape.

Devices:

Devices used in the treatment of actinic keratosis, such as cryotherapy equipment and laser systems, represent a niche but important segment of the market. These devices enable healthcare professionals to perform advanced treatments that are often more effective than topical therapies alone. The adoption of such devices is driven by the growing demand for minimally invasive procedures that yield quick and noticeable results. Furthermore, advancements in technology have enhanced the efficacy and safety of these devices, making them increasingly appealing to dermatologists and patients alike. As the market for actinic keratosis treatments continues to expand, the devices segment is expected to experience significant growth, fueled by continuous innovation and increasing patient demand for advanced therapeutic options.

By Region

North America is projected to dominate the Actinic Keratosis Treatment Market, accounting for over 40% of the total market share. This dominance can be attributed to the high prevalence of actinic keratosis in the region, driven by factors such as increased sun exposure and a significant aging population. The presence of advanced healthcare infrastructure, high disposable income, and a growing number of dermatology clinics further enhance the market landscape. The region is also characterized by active research and development initiatives aimed at innovating treatment modalities, which are likely to contribute to the market's growth. With a favorable regulatory environment that supports the introduction of new treatment options, North America is well-positioned to maintain its leading role in the global market.

Europe follows closely behind, with a strong emphasis on dermatological health and an increasing awareness of skin cancer risks. The European market is expected to grow at a CAGR of around 8.5% during the forecast period, spurred by advancements in treatment technologies and rising healthcare expenditures. The region is home to numerous dermatology clinics and research institutions, contributing to the development and dissemination of effective therapies. Additionally, government initiatives aimed at promoting skin health education are likely to enhance patient awareness and drive the demand for actinic keratosis treatments. As the market evolves, Europe is expected to play a significant role in shaping the future landscape of actinic keratosis management.

Opportunities

The Actinic Keratosis Treatment Market is poised for significant opportunities driven by a combination of factors that enhance treatment accessibility and innovation. One such opportunity lies in the growing trend toward preventive healthcare, as more individuals become aware of the risks associated with sun exposure and the importance of regular skin checks. This awareness is leading to a greater demand for early intervention strategies, thereby increasing the need for effective treatments for actinic keratosis. Healthcare providers are also recognizing the importance of educating patients about the risks of actinic keratosis, encouraging them to pursue preventive measures. As a result, companies that develop and promote educational campaigns and patient engagement initiatives are likely to gain a competitive advantage in the market. Furthermore, collaborations between pharmaceutical companies, research institutions, and dermatology clinics represent an opportunity to drive innovation and enhance the development of new treatment options, ultimately improving patient outcomes.

Another notable opportunity in the Actinic Keratosis Treatment Market is the increasing prevalence of telemedicine and digital health solutions. The COVID-19 pandemic has accelerated the adoption of telehealth platforms, allowing patients to consult dermatologists remotely for skin-related concerns. This shift toward virtual consultations presents an opportunity for healthcare providers to reach a broader patient base, especially those who may have difficulty accessing specialized dermatological care. Additionally, telehealth can facilitate the monitoring and management of actinic keratosis, enabling healthcare providers to offer tailored treatment plans and follow-up support. As telemedicine continues to evolve and integrate with traditional healthcare systems, companies that invest in telehealth solutions and patient engagement tools will be well-positioned to capitalize on this growing trend, ultimately expanding their market presence and enhancing patient care.

Threats

Despite the promising growth prospects within the Actinic Keratosis Treatment Market, there are several threats that could impact its trajectory. One major concern is the presence of alternative treatments and home remedies gaining popularity among patients seeking to avoid more invasive procedures. With the rise of social media and online health forums, individuals may be exposed to unverified information regarding natural treatments, leading them to forego conventional medical interventions. This trend poses a challenge to traditional healthcare providers as they work to encourage proper treatment and management of actinic keratosis. Moreover, the potential for misinformation may lead to increased complications and poor patient outcomes, ultimately undermining the credibility of established treatment options. As patients seek cost-effective solutions, the inclination toward alternative approaches may disrupt the established market dynamics, posing a threat to both existing and new players in the industry.

Another significant threat to the Actinic Keratosis Treatment Market arises from the regulatory challenges associated with the approval and commercialization of new treatment options. The regulatory landscape can be complex and time-consuming, often leading to delays in bringing innovative therapies to market. Stricter regulations governing safety and efficacy can hinder the development of novel treatments, thereby limiting the potential for innovation within the industry. Additionally, high costs associated with regulatory compliance can deter smaller companies from entering the market and competing with established players. As a result, the pace of advancement in treatment options may slow, negatively impacting market growth and limiting patient access to effective therapies. Companies must navigate these regulatory hurdles effectively to ensure timely market entry and maintain a competitive edge in the evolving landscape.

Competitor Outlook

• 3M Company
• Almirall, S.A.
• Dermatologic Technologies Inc.
• Galderma S.A.
• Hugel, Inc.
• Incyte Corporation
• Leo Pharma A/S
• Valeant Pharmaceuticals International, Inc.
• Sun Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Merck & Co., Inc.
• Pfizer Inc.
• Revance Therapeutics, Inc.
• Novartis AG
• Amgen Inc.

The competitive landscape of the Actinic Keratosis Treatment Market is characterized by a diverse array of players, ranging from pharmaceutical giants to specialized dermatological companies. These companies are actively engaged in research and development efforts aimed at bringing innovative treatment options to market. The focus on improving patient outcomes through enhanced efficacy and minimized side effects underscores the competitive nature of this market. Key players are also emphasizing partnerships and collaborations with research institutions to drive the development of new therapies and gain a competitive advantage. Additionally, strategic mergers and acquisitions among leading companies are reshaping the landscape, enabling them to expand their product portfolios and enhance their market presence.

Among the major companies, 3M Company is recognized for its advanced dermatological technologies and innovative treatment solutions, playing a pivotal role in advancing the treatment of actinic keratosis. Almirall, S.A. is another key player, noted for its diverse portfolio of dermatology products, including topical treatments that address a wide range of skin conditions. Galderma S.A. is a significant player in the market with its focus on developing and commercializing prescription products that cater specifically to dermatological needs, further solidifying its position in the industry. Companies like AbbVie Inc. and Merck & Co., Inc. are also notable competitors, leveraging their extensive research capabilities to introduce effective therapies that meet patient demands.

Emerging companies like Revance Therapeutics, Inc., which focus on innovative drug delivery technologies and novel treatment modalities, are likely to reshape the future of actinic keratosis management. These companies are at the forefront of developing cutting-edge solutions that address unmet clinical needs and improve treatment experiences for patients. The competitive landscape is expected to evolve continually as new entrants seek to capitalize on market opportunities and established players strive to maintain their market share. As the actinic keratosis treatment landscape continues to mature, the emphasis on innovation and effective patient care will remain paramount among all competitors in the market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 3M Company
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Hugel, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Novartis AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Pfizer Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Galderma S.A.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Almirall, S.A.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Leo Pharma A/S
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Merck & Co., Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Incyte Corporation
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Revance Therapeutics, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Dermatologic Technologies Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Valeant Pharmaceuticals International, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Actinic Keratosis Treatment Market, By User
    • 6.1.1 Hospitals
    • 6.1.2 Dermatology Clinics
    • 6.1.3 Ambulatory Surgical Centers
  • 6.2 Actinic Keratosis Treatment Market, By Product Type
    • 6.2.1 Creams
    • 6.2.2 Gels
    • 6.2.3 Solutions
    • 6.2.4 Devices
  • 6.3 Actinic Keratosis Treatment Market, By Treatment Type
    • 6.3.1 Topical Medications
    • 6.3.2 Photodynamic Therapy
    • 6.3.3 Cryotherapy
    • 6.3.4 Surgical Procedures
    • 6.3.5 Laser Therapy
  • 6.4 Actinic Keratosis Treatment Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Actinic Keratosis Treatment Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Actinic Keratosis Treatment market is categorized based on

By Treatment Type

• Topical Medications
• Photodynamic Therapy
• Cryotherapy
• Surgical Procedures
• Laser Therapy

By User

• Hospitals
• Dermatology Clinics
• Ambulatory Surgical Centers

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Product Type

• Creams
• Gels
• Solutions
• Devices

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• 3M Company
• Almirall, S.A.
• Dermatologic Technologies Inc.
• Galderma S.A.
• Hugel, Inc.
• Incyte Corporation
• Leo Pharma A/S
• Valeant Pharmaceuticals International, Inc.
• Sun Pharmaceutical Industries Ltd.
• AbbVie Inc.
• Merck & Co., Inc.
• Pfizer Inc.
• Revance Therapeutics, Inc.
• Novartis AG
• Amgen Inc.